Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

The company shocked investors with its loss, although today may also be a major capitulation for the stock.

Why Bausch Health Is Down More Than 24% Today

Bausch (BHC) misses on earnings and sales in the first quarter due to incremental macro pressures and a challenging supply chain environment.

Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down

Bausch + Lomb Corp

LAVAL, QC and VAUGHAN, ON , May 10, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb") and Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") today announced the closing of the initial public offering ("IPO") of Bausch + Lomb. A wholly owned subsidiary of Bausch Health (the "Selling Shareholder") sold 35,000,000 common shares at a public offering price of $18.00 per share for aggregate gross proceeds of $630 million, before deducting underwriting commissions and estimated offering expenses.

Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions

Bausch Health Companies Inc (NYSE: BHC) has reported Q1 revenues of $1.92 billion, down 5% Y/Y. Excluding the unfavorable impact of foreign exchange of $41 million and divestitures & discontinuations of $72 million, revenue was flat organically compared to Q1 FY21.

Bausch Health's Q1 Sales, Profits Fall On Supply Chain Challenges, Cuts FY22 Outlook

Bausch Health (BHC) stock is falling on Tuesday following the release of its earnings report for the first quarter of 2022. The post Bausch Health (BHC) Stock Plunges 25% After Bausch + Lomb IPO appeared first on InvestorPlace.

Bausch Health (BHC) Stock Plunges 25% After Bausch + Lomb IPO

Bausch Health Companies Inc. (NYSE:BHC ) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Joe Papa - Chairman and Chief Executive Officer Thomas Appio - Chief Executive Officer, Bausch Health Tom Vadaketh - Chief Financial Officer, Bausch Health Conference Call Participants Ken Cacciatore - Cowen & Company Chris Schott - JPMorgan Doug Miehm - RBC Capital Markets Greg Fraser - Truist Securities Gary Nachman - BMO Capital Markets Operator Good day, and welcome to the Bausch Health First Quarter 2022 Earnings Conference Call. All participants will be in listen only mode.

Bausch Health Companies Inc. (BHC) CEO Joe Papa on Q1 2022 Results - Earnings Call Transcript

Shares of Bausch Health Cos. Inc. BHC, -19.58% tumbled 32.0% in premarket trading on Tuesday after the company missed revenue and earnings expectations for the first quarter.

Bausch Health's stock falls 32% on revenue and earnings miss in Q1

First-Quarter 2022 Financial Results Revenues of $1.918 Billion GAAP Net Loss of $69 Million Adjusted EBITDA (non-GAAP) 1  of $732 Million Bausch + Lomb Commences Trading Under "BLCO" Ticker Following IPO2 Updates Full-Year Revenue and Adjusted EBITDA (non-GAAP)1 Guidance Ranges LAVAL, QC, May 10, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we") today announced its first-quarter 2022 financial results. "Our organic3 growth in the first quarter of 2022 was stable compared to the same quarter last year, despite incremental macro pressures and a challenging supply chain environment," said Thomas J.

Bausch Health Companies Inc. Announces First-Quarter 2022 Results

RBC Capital Markets expects Bausch Health Companies Inc (NYSE: BHC) Q1 FY22 revenue of $2.02 billion (previous $2.04 billion; consensus $2.05 billion) and adjusted EBITDA of $799 million (previous $816 million; consensus $819 million).  The forecasts suggest a 0.4% y/y.

RBC Capital: What To Expect When Bausch Health Companies Reports Q1 Tomorrow

Catalyst Pharmaceuticals

Epizyme

Exelixis

Reata Pharmaceuticals

Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.

Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

LAVAL, QC , May 6, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (Bausch Health) today announced its full leadership team and Board of Directors, including Chief Executive Officer (CEO) Thomas J. Appio.1 Upon completion of the initial public offering (IPO) of the Bausch + Lomb eye health business,2 former CEO Joseph C.

Bausch Health Announces Thomas J. Appio As Chief Executive Officer

Bausch + Lomb, a well-known leader in eye care, is about to hit Wall Street in what investment bankers almost certainly hope will jump-start a weak initial public offering (IPO) market. Bausch Health Companies (BHC) is a global healthcare stock that develops pharmaceuticals, medical devices and over-the-counter medications, with focus areas in eye health, gastroenterology and dermatology.

Bausch + Lomb IPO: What You Need to Know

NOV03 Met Primary Endpoints for Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction in Both Phase 3 Trials VAUGHAN, ON and LAVAL, QC and HEIDELBERG, Germany , May 3, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced that data from the second pivotal Phase 3 trial (MOJAVE) of investigational treatment NOV03 (perfluorohexyloctane) were presented virtually yesterday at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. NOV03 is being investigated as a first-in-class treatment with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).

Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting

Here's what investors may want to know about the upcoming BLCO stock IPO, as Bausch + Lomb is split off from its parent company this week. The post BLCO Stock IPO: When Does Bausch + Lomb Go Public?

BLCO Stock IPO: When Does Bausch + Lomb Go Public? What Is the Bausch + Lomb IPO Price Range?

The U.S. initial public offering market is bracing for what is expected to be the second-biggest deal of the year so far this week, that of eyecare company Bausch & Lomb, which is expected to raise up to $840 million at a valuation of more than $8 billion.

IPO Report: U.S. IPO market bracing for second-biggest deal of the year so far in eyecare health company Bausch + Lomb

LAVAL, QC , April 29, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its first-quarter financial results on Tuesday, May 10, 2022. Bausch Health will host a conference call and live web cast at 8:00 a.m.

Bausch Health Companies Inc. Will Release First-Quarter 2022 Financial Results On May 10

LAVAL, QC and VAUGHAN, ON , April 28, 2022 /PRNewswire/ -- Bausch + Lomb Corporation ("Bausch + Lomb"), a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the launch of its initial public offering ("IPO") and the commencement of the roadshow for the IPO. A wholly owned subsidiary of Bausch Health (the "Selling Shareholder") is offering 35.0 million common shares of Bausch + Lomb.

Bausch + Lomb Corporation Announces Launch of IPO and Roadshow

LAVAL, QC and VAUGHAN, ON , April 28, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that, in connection with its previously announced intention to separate its eye health business, it has entered into an arrangement agreement with, among others, its wholly owned subsidiary Bausch + Lomb Corporation ("Bausch + Lomb"). The arrangement agreement sets out the terms and conditions of the proposed transactions by which Bausch Health currently expects to transfer all or a portion of the remaining direct or indirect equity interest in Bausch + Lomb following completion of the initial public offering of Bausch + Lomb (the "Bausch + Lomb IPO") and expiration or waiver of the IPO lockup to Bausch Health shareholders.

Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation

13 Poster Presentations Include Results from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane), as well as Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use VAUGHAN, ON and LAVAL, QC , April 28, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the presentation of 13 scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in Denver, Colo., from May 1-4, 2022, and virtually from May 11-12, 2022.

Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting

Four Poster Presentations Will Include New Analyses on ARAZLO® LAVAL, QC , April 27, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced the presentation of four poster presentations during the Florida Society of Dermatology Physician Assistants (FSDPA) 2022 New Wave Dermatology Conference, which will take place in Coral Gables, Fla. from April 28 - May 1, 2022.

Ortho Dermatologics Will Present Data at the 2022 Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference

NOV03 Met Both Primary Endpoints for Signs and Symptoms of Dry Eye Disease VAUGHAN, ON and LAVAL, QC and HEIDELBERG, Germany , April 25, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced that data from the first pivotal Phase 3 trial (GOBI) of NOV03 (perfluorohexyloctane), which is being investigated as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD), was presented yesterday as part of a podium presentation on April 24, 2022, at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C.  "The data show that NOV03 met both primary endpoints of total Corneal Fluorescein Staining, a measure that assesses damage to the eye, and visual analogue scale dryness score at day 57," said Joseph Tauber, M.D.

Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting

VAUGHAN, ON and LAVAL, QC and TRENTON, N.J. , April 21, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced its exclusive ONE by ONE and Biotrue® Eye Care Recycling programs have recycled a total of 48,235,850 million units, or 290,145 pounds, of used contact lenses, eye care and lens care materials, which is the equivalent of the weight of approximately 31 elephants.1 Both programs are made possible through a collaboration with TerraCycle®, a world leader in the collection and repurposing of hard-to-recycle post-consumer waste.

Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs

Bausch Health Companies has lost 25% of its equity value so far this year. Management continues to execute on their strategic alternatives plan to drive shareholder value.

Revisiting Bausch: $7.5B Market Cap Too Low

LAVAL, Quebec, and VAUGHAN, Ontario , April 20, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that, in connection with its previously announced intention to separate its eye health business (the "Separation"), its wholly owned subsidiary, Bausch + Lomb Corporation ("Bausch + Lomb"), is seeking to enter into a new credit agreement (the "Bausch + Lomb Credit Agreement"), which is expected to include a $2.5 billion term B loan facility (the "Term Loan Facility") and $500 million revolving facility (the "Revolving Credit Facility", and together with the Term Loan Facility, the "Credit Facilities"). The Term Loan Facility is expected to mature in 2027.

Bausch + Lomb Corporation Seeking to Enter Into New Credit Facilities to Facilitate Previously Announced Separation from Bausch Health

10 Podium Presentations, Two Posters Include Results from the First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) VAUGHAN, ON and LAVAL, QC , April 18, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the presentation of 10 podium presentations and two poster presentations during the American Society of Cataract and Refractive Surgery annual meeting, which will take place from April 22-26, 2022 in Washington, D.C. The presentations will include results from the first of two pivotal Phase 3 trials of the investigational treatment, NOV03 (perfluorohexyloctane), as well as from several studies involving the company's surgical technologies.

News for Bausch Health Companies Inc Stock (BHC)